Shots: The company holds the inclusion and initiation of treatment in ongoing 3 studies i.e P-III in mastocytosis (AB15003), P-III study in AML (AB19001) & P-II in COVID (AB20001) for […]readmore
Tags : Discontinues
Shots: Spring Bank has discontinued the development of Inarigivir soproxil due to the occurrence of one patient death in its P-IIb CATALYST study The discontinuation allows Spring Bank to focus […]readmore
Shots: The discontinuation of P-III study is due to the inability of Fremanezumab to meet its 1EPs i.e, reduction in weekly number of cluster headache attacks in 4wks. In Jun’18, […]readmore
Shots: The P-III CREAD-1 and 2 study involves assessing of Crenezumab vs PBO in 1500 patients with early AD with confirmed evidence of cerebral beta-amyloid pathology (CSF or amyloid PET) […]readmore